Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Serum proteome pool changes in type 2 diabetic patients treated with anakinra

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Leukocyte telomere length is associated with elevated plasma glucose and HbA1c in young healthy men independent of birth weight

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased leptin, decreased adiponectin and FGF21 concentrations in adolescent offspring of women with gestational diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Low carbohydrate diet elevates blood sphingomyelin in people with type 1 diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  • Mette Koefoed
  • Claus M. Larsen
  • Mirjam V. Faulenbach
  • Allan Vaag
  • Jan A. Ehses
  • Marc Y. Donath
  • James Norton McGuire
  • Flemming Pociot
  • Thomas Mandrup-Poulsen
Vis graf over relationer

Introduction: High glucose concentrations induce the production of IL-1β in human pancreatic beta cells leading to impaired insulin secretion, decreased cell proliferation and apoptosis. Blockade of IL-1 signalling with the recombinant human IL-1 receptor antagonist anakinra reduces HbA1c in patients with type 2 diabetes. The aims of the present study were to identify: (1) candidate surrogates for improved glycemia in type 2 diabetic patients following treatment with anakinra, (2) proteins that change serum concentration because of anakinra treatment and (3) candidate biomarkers that may predict improved glycemia in type 2 diabetic subjects treated with anakinra. Methods: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry was used to analyse serum from 67 type 2 diabetic patients who had received either placebo or anakinra for 13 weeks. Immunodepletion with magnetic protein G bead-coupled antibodies were used to identify three proteins and Western blotting confirmed the biomarker concentration pattern of four proteins. Results: Twelve proteins, including transthyretin (TTR) and transferrin (Tf), were identified as candidate surrogates for improved glycemia. Six proteins, including retinol-binding protein 4 (RPB4) and a protein tentatively identified as modified apolipoprotein-A1 (apo-AI), increased expression as a consequence of anakinra treatment and four proteins were candidate biomarkers that may predict improved glycemia following anakinra treatment. Furthermore, we found increased RBP4 to be associated with improved beta cell secretory function and increased TTR, RBP4 and modified apo-AI (peak at 28,601 Da) to be associated with decreased inflammation. Conclusions: Anakinra-induced changes in the serum proteome pool associated with a decreased cardiovascular disease risk, reduced inflammation and improved beta cell secretory function.

OriginalsprogEngelsk
TidsskriftClinical Proteomics
Vol/bind6
Udgave nummer4
Sider (fra-til)153-161
Antal sider9
ISSN1542-6416
DOI
StatusUdgivet - 1 dec. 2010
Eksternt udgivetJa

ID: 55873113